

EARLY Prodrromal Alzheimer's Study

Aim

To investigate the efficacy and safety of JNJ-54861911, a beta secretase inhibitor, in subjects who are asymptomatic or at risk of developing Alzheimer's disease (AD).

Phase 2b/3

Randomized, double-blind, placebo-controlled, parallel group, multicenter study to investigate the effect of JNJ-54861911 in reducing the development of AD.

Hypothesis

Beta secretase inhibition delays the development of AD in asymptomatic subjects at risk for AD, by preventing amyloid formation.

Ethics approval

Bellberry Human Research Ethics
Committee 2015-07-532

Status

Currently enrolling

Trial NCT02569398

Funding

- Janssen Research & Development LLC, pharmaceutical company of Johnson & Johnson
- Neurodegenerative Disorders Research Pty Ltd

Criteria

Participants must be 60–85 years old and not be demented.

If 60–64 years of age, participants must have a family history of AD, or APOE ϵ 4 genotype, or evidence of elevated amyloid accumulation (CSF procedure).

Duration of study

4.5 years (attend clinic monthly for the first year and then every 3 months)

Principal Investigator

Professor Peter K Panegyres, MD PhD FRACP
Principal Investigator
Neurodegenerative Disorders Research Pty Ltd
4 Lawrence Avenue, West Perth WA 6005
Phone: (08) 9481 6293
Fax: (08) 9481 6294
Email: research@ndr.org.au